Dr. Burris on Updated MONALEESA-2 Trial Results for HR+ Breast Cancer

Video

Howard A. "Skip" Burris, MD, president of Clinical Operations and chief medical officer at Sarah Cannon Research Institute, discusses updated findings from the MONALEESA-2 trial, which explored first-line treatment with ribociclib plus letrozole in patients with hormone receptor (HR)-positive, HER2-negative breast cancer.

Howard A. "Skip" Burris, MD, president of Clinical Operations and chief medical officer at Sarah Cannon Research Institute, discusses updated findings from the MONALEESA-2 trial, which explored first-line treatment with ribociclib plus letrozole in patients with hormone receptor (HR)-positive, HER2-negative breast cancer.

<<<

View more from the 2016 San Antonio Breast Cancer Symposium

Related Videos
Stephen V. Liu, MD
S. Vincent Rajkumar, MD
Samilia Obeng-Gyasi, MD, MPH,
Nan Chen, MD
Timothy Yap, MBBS, PhD, FRCP
Parul N Barry, MD,
Angela Jia, MD, PhD, of University Hospitals
Robert Wang, MD, of Fox Chase Cancer Center
Alexander Kutikov, MD, FACS, of Fox Chase Cancer Center
Roger Li, MD, of Moffitt Cancer Center